FDA grants fast track designation for Novartis’ LNA043 to treat osteoarthritis

FDA grants fast track designation for Novartis’ LNA043 to treat osteoarthritis

Submitted by admin on September 3, 2021 - 11:01am
Source: 
Pharmaceutical Business Review
News Tags: 
FDA
Novartis
osteoarthritis of the knee
LNA043
Headline: 
FDA grants fast track designation for Novartis’ LNA043 to treat osteoarthritis
snippet: 

The US Food and Drug Administration (FDA) has granted fast track designation for Novartis’ agonist LNA043 to treat knee osteoarthritis.

Do Not Allow Advertisers to Use My Personal information